The recent GST reforms introduced in September 2025 mark a landmark shift for India’s pharmaceutical and healthcare sectors, aimed at making healthcare more affordable and accessible to the public. With significant reductions in GST rates across medicines, medical devices, and related services, the reforms are expected to lower treatment costs and boost industry growth.
Key Takeaways
GST on all drugs, except 36 specified lifesaving medicines, has been reduced from 12% to 5%, benefiting chronic disease and cancer patients with exempted drugs
Medical apparatus and devices now attract GST at 5%, down from 18%, lowering costs for hospitals and diagnostic labs
Reductions also extend to essential medical supplies like bandages, diagnostic kits, and glucometers, making healthcare equipment more affordable
The reforms promote equitable healthcare access and strengthen India’s global leadership in pharma manufacturing
Industry leaders hail these reforms as a catalyst for increased patient affordability, innovation, and expansion of healthcare services across urban and rural India
This reform underscores government commitment to a citizen-centric healthcare ecosystem, catalyzing positive impacts on both patients and providers.
Sources: EY India, PIB India, Lakshmisri, Express Healthcare